uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Carlson, Marie
Alternative names
Publications (10 of 48) Show all publications
Lampinen, M., Vessby, J., Fredricsson, A., Wanders, A., Rorsman, F. & Carlson, M. (2019). High serum sCD40 and a distinct colonic T cell profile in ulcerative colitis associated with primary sclerosing cholangitis.. Journal of Crohn's & Colitis, 13(3), 341-350
Open this publication in new window or tab >>High serum sCD40 and a distinct colonic T cell profile in ulcerative colitis associated with primary sclerosing cholangitis.
Show others...
2019 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 13, no 3, p. 341-350Article in journal (Refereed) Published
Abstract [en]

Background and aims: There is a strong association between primary sclerosing cholangitis (PSC) and ulcerative colitis (UC), but the immunological link between the two diseases is obscure. We compared serum cytokine profiles of patients with PSC-UC and UC, and investigated a number of selected cytokines in colonic biopsy samples. We also assessed the presence and activation of T-cells in peripheral blood and colonic mucosa.

Methods: Serum samples from 22 patients with PSC-UC, 28 patients with UC and 19 controls were analyzed by a proximity extension assay including 92 inflammatory cytokines. Biopsies from caecum, sigmoid colon and rectum were collected from the same patients. Quantitative analysis for IFN-γ, IL-2, IL-4, IL-5, IL-13, IL-17A/ E/F, IL-21, IL-22, IL-23 and IL-27 was carried out on tissue homogenates. T-cell phenotype was evaluated by flow cytometry.

Results: By multivariate analysis we identified a cluster of serum cytokines with higher levels in PSC-UC, and sCD40 in particular was strongly associated to this patient group. In contrast, colonic cytokines were only modestly increased in PSC-UC, whereas several Th1, Th2 and Th17-associated cytokines were increased in UC. Patients with PSC-UC had increased colonic levels of CXCR3-positive CD8+ T-cells but fewer CD25-positive CD4+ T-cells. An increased CRTH2/CXCR3-quote indicated a predominance of Th-2 type CD4+ T-cells in UC-patients.

Conclusions: Our study reveals different cytokine- and T-cell profiles in PSC-UC and UC, with higher systemic levels of cytokines in PSC-UC, and a more pronounced colonic inflammation in UC. Serum sCD40 could potentially be investigated as a marker for PSC in UC.

National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-365803 (URN)10.1093/ecco-jcc/jjy170 (DOI)000464942000011 ()30383225 (PubMedID)
Funder
Swedish Foundation for Strategic Research Swedish Society of MedicineStiftelsen Olle Engkvist Byggmästare
Available from: 2018-11-14 Created: 2018-11-14 Last updated: 2019-05-09Bibliographically approved
Amcoff, K., Cao, Y., Zhulina, Y., Lampinen, M., Halfvarson, J. & Carlson, M. (2019). Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 54(10), 1237-1244
Open this publication in new window or tab >>Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease
Show others...
2019 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 54, no 10, p. 1237-1244Article in journal (Refereed) Published
Abstract [en]

Background: Non-invasive markers for predicting relapse would be a useful tool for the management of patients with inflammatory bowel disease. Eosinophil granulocytes and their granule proteins eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) have previously been shown to reflect disease activity in Crohn's disease and ulcerative colitis.

Aim: To examine the capacity of faecal ECP and EDN to predict relapse in ulcerative colitis and Crohn's disease, and to compare these proteins with faecal calprotectin.

Methods: Patients with Crohn's disease (n?=?49) and ulcerative colitis (n?=?55) were followed prospectively until relapse or end of the two-year study period. Faecal samples were obtained every third month. The predictive value of ECP and EDN was assessed in Cox regression models.

Results: In ulcerative colitis, a doubled EDN or ECP concentration was associated with a 31% and 27% increased risk of relapse, respectively. EDN levels were increased both at relapse and three months prior. By contrast, in Crohn's disease, the concentration of EDN was higher among patients in remission than in those who relapsed. Correlations between faecal calprotectin, ECP and EDN were observed in both diseases.

Conclusions: We demonstrate that the risk of relapse in ulcerative colitis can be predicted by consecutively measuring faecal EDN every third month, and suggest EDN as a complementary faecal marker to calprotectin to predict future relapse in ulcerative colitis. Our finding of higher EDN in Crohn's disease-patients staying in remission than in those who relapsed indicates different functions of the protein in ulcerative colitis and Crohn's disease.

Keywords
Inflammatory bowel disease, Crohn's disease, ulcerative colitis, biomarkers, eosinophils, inflammation
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-399012 (URN)10.1080/00365521.2019.1670251 (DOI)000488503800001 ()31577465 (PubMedID)
Funder
Swedish Foundation for Strategic Research , RB13-0160Swedish Research Council, 521-2011-2764
Available from: 2019-12-16 Created: 2019-12-16 Last updated: 2019-12-16Bibliographically approved
Eberhardson, M., Hedin, C. R. H., Carlson, M., Tarnawski, L., Levine, Y. A. & Olofsson, P. S. (2019). Towards improved control of inflammatory bowel disease. Scandinavian Journal of Immunology, 89(3), Article ID e12745.
Open this publication in new window or tab >>Towards improved control of inflammatory bowel disease
Show others...
2019 (English)In: Scandinavian Journal of Immunology, ISSN 0300-9475, E-ISSN 1365-3083, Vol. 89, no 3, article id e12745Article, review/survey (Refereed) Published
Abstract [en]

Inflammatory bowel disease (IBD) is characterized by activation of both the innate and adaptive immune system in genetically susceptible individuals, resulting in chronic intestinal inflammation. The triggers that initiate and perpetuate this continuous inflammation are the subject of much speculation and research, although the central role of the intestinal microbiota is recognized, and is even a target for treatment in some circumstances. The mainstay of modern IBD treatment is suppression of the immune response towards as yet unspecified antigens, and conventional therapy includes corticosteroids, 5-aminosalicylic acid (5-ASA), thiopurines and methotrexate. Reducing activity of specific mediators has proven efficacious, including adhesion molecules, such as the gut-homing integrin alpha(4)beta(7) expressed on the surface of circulating immune cells, and cytokines, such as tumour necrosis factor alpha (TNF-alpha). This has been achieved using biologic agents including monoclonal antibodies. Recent discoveries in immunology and neuroscience have revealed that signals in the peripheral nervous system regulate inflammation, including levels of TNF-alpha. The understanding of the mechanisms of the neuro-immune communication involved in inflammation control in the gut is evolving, but is as yet incomplete. Clinical studies using implanted vagus nerve stimulators for treatment of IBD show encouraging results. Accordingly, the neural reflex control of inflammation is emerging as a potential therapeutic target in treatment of IBD. Here, we review current therapeutic options and neural reflex control of gut immunity in the context of intestinal inflammation.

Place, publisher, year, edition, pages
John Wiley & Sons, 2019
Keywords
autoimmunity, human, inflammation, mucosa, mucosal immunity, neutrophils, T Cells
National Category
Immunology in the medical area Immunology Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-379419 (URN)10.1111/sji.12745 (DOI)000459818000007 ()30582196 (PubMedID)
Available from: 2019-03-19 Created: 2019-03-19 Last updated: 2019-03-19Bibliographically approved
Lampinen, M., Fredricsson, A., Vessby, J., Martinez, J. F., Wanders, A., Rorsman, F. & Carlson, M. (2018). Downregulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis. Paper presented at 10th Biennial Symposium of the International-Eosinophil-Society, JUL 19-23, 2017, Gothenburg, SWEDEN. Journal of Leukocyte Biology, 104(1), 173-183
Open this publication in new window or tab >>Downregulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis
Show others...
2018 (English)In: Journal of Leukocyte Biology, ISSN 0741-5400, E-ISSN 1938-3673, Vol. 104, no 1, p. 173-183Article in journal (Refereed) Published
Abstract [en]

Primary sclerosing cholangitis (PSC) is a chronic bile duct inflammation strongly connected to ulcerative colitis (UC). PSC is associated with an increased risk of colon cancer, but the link between the intestinal and the bile duct inflammation is still unknown. Also, the involvement of intestinal immune cells in the pathogenesis of PSC remains to be determined. The eosinophil granulocyte is one of the immune cells implicated in the inflammatory process of ulcerative colitis. This study was performed to determine how the accumulation and activation of intestinal eosinophils may differ between UC with and without concomitant PSC, and how this may be influenced by the cytokine/chemokine profile of the intestinal compartment. Eosinophils from peripheral blood and multiple parts of the colon were analyzed by flow cytometry. The intestinal level of inflammatory mediators was assessed using a multiplex proximity extension assay and a quantitative immunoassay. We found that colonic eosinophils were more abundant in both UC and PSC-UC compared with controls, but that their expression of activation markers was significantly increased in UC only. The colonic level of pro-inflammatory cytokines was increased in active UC but not in PSC-UC. In conclusion, we show for the first time that eosinophil activation phenotype discriminates between UC and PSC-UC, and that this may depend on the local cytokine profile of the colonic mucosa. Lower expression of activation markers on eosinophils in UC with concomitant PSC may depend on the local protein profile of the colonic mucosa.

Place, publisher, year, edition, pages
WILEY, 2018
Keywords
eotaxin-1, flow cytometry, IL-33, proximity extension assay
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-358268 (URN)10.1002/JLB.3MA0517-175R (DOI)000435944300016 ()29603385 (PubMedID)
Conference
10th Biennial Symposium of the International-Eosinophil-Society, JUL 19-23, 2017, Gothenburg, SWEDEN
Funder
Stiftelsen Olle Engkvist Byggmästare
Available from: 2018-08-29 Created: 2018-08-29 Last updated: 2018-11-28Bibliographically approved
Amcoff, K., Cao, Y., Zhulina, Y., Lampinen, M., Halfvarson, J. & Carlson, M. (2018). Prognostic significance of eosinophil granule proteins in inflammatory bowel disease. Journal of Crohn's & Colitis, 12, S181-S182
Open this publication in new window or tab >>Prognostic significance of eosinophil granule proteins in inflammatory bowel disease
Show others...
2018 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, p. S181-S182Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
OXFORD UNIV PRESS, 2018
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-357063 (URN)000427318900292 ()
Available from: 2018-08-13 Created: 2018-08-13 Last updated: 2018-08-13Bibliographically approved
Moshkovits, I., Reichman, H., Karo-Atar, D., Rozenberg, P., Zigmond, E., Haberman, Y., . . . Munitz, A. (2017). A key requirement for CD300f in innate immune responses of eosinophils in colitis. Mucosal Immunology, 10(1), 172-183
Open this publication in new window or tab >>A key requirement for CD300f in innate immune responses of eosinophils in colitis
Show others...
2017 (English)In: Mucosal Immunology, ISSN 1933-0219, E-ISSN 1935-3456, Vol. 10, no 1, p. 172-183Article in journal (Refereed) Published
Abstract [en]

Eosinophils are traditionally studied in the context of type 2 immune responses. However, recent studies highlight key innate immune functions for eosinophils especially in colonic inflammation. Surprisingly, molecular pathways regulating innate immune activities of eosinophil are largely unknown. Wehave recently shown that the CD300f is highly expressed by colonic eosinophils. Nonetheless, the role of CD300f in governing innate immune eosinophil activities is ill-defined. RNA sequencing of 162 pediatric Crohn's disease patients revealed upregulation of multiple Cd300 family members, which correlated with the presence of severe ulcerations and inflammation. Increased expression of CD300 family receptors was also observed in active ulcerative colitis (UC) and in mice following induction of experimental colitis. Specifically, the expression of CD300f was dynamically regulated in monocytes and eosinophils. Dextran sodium sulfate (DSS)-treated Cd300f (-/-) mice exhibit attenuated disease activity and histopathology in comparison with DSS-treated wild type (WT). Decreased disease activity in Cd300f (-/-) mice was accompanied with reduced inflammatory cell infiltration and nearly abolished production of pro-inflammatory cytokines. Monocyte depletion and chimeric bone marrow transfer experiments revealed a cell-specific requirement for CD300f in innate immune activation of eosinophils. Collectively, we uncover a new pathway regulating innate immune activities of eosinophils, a finding with significant implications in eosinophil-associated gastrointestinal diseases.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-319892 (URN)10.1038/mi.2016.37 (DOI)000395807400017 ()27118491 (PubMedID)
Available from: 2017-04-10 Created: 2017-04-10 Last updated: 2017-11-29Bibliographically approved
Amcoff, K., Stridsberg, M., Lampinen, M., Magnuson, A., Carlson, M. & Halfvarson, J. (2017). Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time. Scandinavian Journal of Gastroenterology, 52(3), 344-350
Open this publication in new window or tab >>Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time
Show others...
2017 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 52, no 3, p. 344-350Article in journal (Refereed) Published
Abstract [en]

Objective: With several faecal calprotectin (FC) assays on the market, it has been difficult to define a uniform threshold for discriminating between remission and active disease in patients with inflammatory bowel disease (IBD). We aimed to compare the results of different FC-assays in IBD patients, followed over time.Material and methods: IBD patients provided faecal samples and reported clinical activity every third month prospectively over a two year period. FC was measured with two ELISA - (Buhlmann and Immunodiagnostik) and one automated fluoroimmunoassay (Phadia).Results: In total, 13 patients provided 91 faecal samples. The median (IQR) concentration of FC was higher at active disease than at remission for all assays: Buhlmann 845 (1061-226) g/g versus 62 (224-39) g/g, Phadia 369 (975-122) g/g versus 11 (52-11) g/g, and Immundiagnostik 135 (302-69) g/g versus 8 (56-4) g/g. The Buhlmann assay produced the largest absolute difference but the corresponding relative difference seemed to be more pronounced when analysed by the Phadia - (ratio of means 8.5; 95% CI 3.3-21.9) or the Immundiagnostik assay (ratio of means 7.4; 95% CI 3.1-17.6) than by the Buhlmann assay (ratio of means 5.3; 95% CI 2.7-10.6). Consequently, the specificity for discriminating active disease from remission varied between assays (34-75%) when the cut-off 50g/g was used, whereas the differences in sensitivity were less pronounced.Conclusions: Cross-comparisons revealed overall poor agreement between the assays as well as differences in the dynamics of FC. These findings suggest that standardisation of the method is needed to implement FC as a disease monitoring tool at large-scale.

Keywords
Biomarker, Crohn's disease, faecal calprotectin, inflammatory bowel disease, ulcerative colitis
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-316426 (URN)10.1080/00365521.2016.1256424 (DOI)000392488800015 ()27881032 (PubMedID)
Funder
Swedish Research Council, 521-2011-2764
Available from: 2017-03-01 Created: 2017-03-01 Last updated: 2017-11-29Bibliographically approved
Wagner, M., Sjöberg, K., Vigren, L., Olesen, M., Benoni, C., Toth, E. & Carlson, M. (2016). Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scandinavian Journal of Gastroenterology, 51(7), 835-841
Open this publication in new window or tab >>Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea
Show others...
2016 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 51, no 7, p. 835-841Article in journal (Refereed) Published
Abstract [en]

Objective: Colonoscopy with biopsy sampling is often performed to detect collagenous colitis (CC) and lymphocytic colitis (LC) in patients with chronic non-bloody diarrhea. However, the diagnostic yield is low and incurs high costs. Fecal calprotectin (FC) and myeloperoxidase (MPO) indicate intestinal inflammation in ulcerative colitis (UC) and Crohn's disease (CD). In CC, elevated fecal levels of eosinophil protein X (EPX) and eosinophil cationic protein (ECP) have been reported. We aimed to evaluate if F-EPX, F-ECP, FC, and F-MPO could predict the diagnostic outcome in patients with chronic non-bloody diarrhea referred to colonoscopy. We also evaluated serum (S) EPX and ECP in this regard. Methods: Of 67 included patients, 63 (94%) underwent colonoscopy with biopsy sampling. Fecal EPX, F-ECP, FC, F-MPO, S-EPX, and S-ECP were analyzed. Results: Diagnostic outcome: normal: n = 46 (73%), CC: n = 9 (14%), LC: n = 4 (6%), UC: n = 2 (3%), CD: n = 2 (3%). Higher levels of F-EPX and F-ECP were found in CC compared to a normal diagnostic outcome (p = 0.01). No change was noted in any of the fecal markers in LC. When all of the fecal markers were normal the probability of a normal diagnostic outcome was 92%. We found no differences in S-EPX and S-ECP between the groups. Conclusion: Elevated F-EPX and F-ECP could predict CC. None of the fecal markers predicted LC. Serum-EPX and S-ECP are not useful for the diagnosis of CC, LC, UC, or CD. With normal levels in all of the analyzed fecal markers, there is a low probability of a pathologic diagnostic outcome.

Keywords
Collagenous colitis, eosinophil, eosinophil cationic protein, eosinophil protein X, fecal markers
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-299533 (URN)10.3109/00365521.2016.1141432 (DOI)000377451400010 ()26854205 (PubMedID)
Funder
Stiftelsen Olle Engkvist Byggmästare
Available from: 2016-07-22 Created: 2016-07-22 Last updated: 2017-11-28Bibliographically approved
Lampinen, M., Fredricsson, A., Vessby, J., Wanders, A., Rorsman, F. & Carlson, M. (2016). Expression of the liver homing receptor CXCR3+on colonic CD8+T lymphocytes in patients with primary sclerosing cholangitis provides a possible link between colonic and biliary duct inflammation. Journal of Crohn's & Colitis, 10, S109-S109
Open this publication in new window or tab >>Expression of the liver homing receptor CXCR3+on colonic CD8+T lymphocytes in patients with primary sclerosing cholangitis provides a possible link between colonic and biliary duct inflammation
Show others...
2016 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, p. S109-S109Article in journal, Meeting abstract (Other academic) Published
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-299652 (URN)000374496600160 ()
Available from: 2016-07-25 Created: 2016-07-25 Last updated: 2017-11-28Bibliographically approved
Zhulina, Y., Cao, Y., Amcoff, K., Carlson, M., Tysk, C. & Halfvarson, J. (2016). Prognostic significance of serial faecal calprotectin in inflammatory bowel disease. Journal of Crohn's & Colitis, 10, S315-S318
Open this publication in new window or tab >>Prognostic significance of serial faecal calprotectin in inflammatory bowel disease
Show others...
2016 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, p. S315-S318Article in journal, Meeting abstract (Other academic) Published
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-299654 (URN)000374496600551 ()
Available from: 2016-07-25 Created: 2016-07-25 Last updated: 2017-11-28Bibliographically approved
Organisations

Search in DiVA

Show all publications